These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 27755105)

  • 21. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.
    Laird GM; Bullen CK; Rosenbloom DI; Martin AR; Hill AL; Durand CM; Siliciano JD; Siliciano RF
    J Clin Invest; 2015 May; 125(5):1901-12. PubMed ID: 25822022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective BCL-X
    Ren Y; Huang SH; Macedo AB; Ward AR; Alberto WDC; Klevorn T; Leyre L; Copertino DC; Mota TM; Chan D; Truong R; Rohwetter T; Zumbo P; Dündar F; Betel D; Kovacs C; Benko E; Bosque A; Jones RB
    J Virol; 2021 Jul; 95(15):e0242520. PubMed ID: 33980597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8+ T Cells Limit the Killing of HIV-1 Reactivated Cells.
    Ruiz A; Blanch-Lombarte O; Jimenez-Moyano E; Ouchi D; Mothe B; Peña R; Galvez C; Genescà M; Martinez-Picado J; Goulder P; Barnard R; Howell B; Clotet B; Prado JG
    Front Immunol; 2018; 9():3162. PubMed ID: 30723480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design.
    Ke R; Conway JM; Margolis DM; Perelson AS
    JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review.
    Debrabander Q; Hensley KS; Psomas CK; Bramer W; Mahmoudi T; van Welzen BJ; Verbon A; Rokx C
    J Virus Erad; 2023 Sep; 9(3):100342. PubMed ID: 37663575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hybrid nanocarriers incorporating mechanistically distinct drugs for lymphatic CD4
    Cao S; Slack SD; Levy CN; Hughes SM; Jiang Y; Yogodzinski C; Roychoudhury P; Jerome KR; Schiffer JT; Hladik F; Woodrow KA
    Sci Adv; 2019 Mar; 5(3):eaav6322. PubMed ID: 30944862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.
    Marsden MD; Wu X; Navab SM; Loy BA; Schrier AJ; DeChristopher BA; Shimizu AJ; Hardman CT; Ho S; Ramirez CM; Wender PA; Zack JA
    Virology; 2018 Jul; 520():83-93. PubMed ID: 29800728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Current Status of Latency Reversing Agents for HIV-1 Remission.
    Rodari A; Darcis G; Van Lint CM
    Annu Rev Virol; 2021 Sep; 8(1):491-514. PubMed ID: 34586875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Counteracting Akt Activation by HIV Protease Inhibitors in Monocytes/Macrophages.
    Pasquereau S; Kumar A; Abbas W; Herbein G
    Viruses; 2018 Apr; 10(4):. PubMed ID: 29652795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanistic differences underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents.
    Telwatte S; Kim P; Chen TH; Milush JM; Somsouk M; Deeks SG; Hunt PW; Wong JK; Yukl SA
    AIDS; 2020 Nov; 34(14):2013-2024. PubMed ID: 32910065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishment, Persistence, and Reactivation of Latent HIV-1 Infection in Renal Epithelial Cells.
    Baker EJ; Hughes K; Travieso T; Klotman ME; Blasi M
    J Virol; 2022 Jul; 96(14):e0062422. PubMed ID: 35867560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Peptide Self-Assembly Nanoparticles Loaded with Panobinostat to Activate Latent Human Immunodeficiency Virus.
    Kuai Q; Wang Y; Gao F; Qi Y; Wang R; Wang Y; Lu X; Zhao Y; Nie G; He M; Zhou H; Jiang X; Ren S; Yu Q
    J Biomed Nanotechnol; 2019 May; 15(5):979-992. PubMed ID: 30890229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-throughput Characterization of HIV-1 Reservoir Reactivation Using a Single-Cell-in-Droplet PCR Assay.
    Yucha RW; Hobbs KS; Hanhauser E; Hogan LE; Nieves W; Ozen MO; Inci F; York V; Gibson EA; Thanh C; Shafiee H; El Assal R; Kiselinova M; Robles YP; Bae H; Leadabrand KS; Wang S; Deeks SG; Kuritzkes DR; Demirci U; Henrich TJ
    EBioMedicine; 2017 Jun; 20():217-229. PubMed ID: 28529033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral T Follicular Helper Cells Are the Major HIV Reservoir within Central Memory CD4 T Cells in Peripheral Blood from Chronically HIV-Infected Individuals on Combination Antiretroviral Therapy.
    Pallikkuth S; Sharkey M; Babic DZ; Gupta S; Stone GW; Fischl MA; Stevenson M; Pahwa S
    J Virol; 2015 Dec; 90(6):2718-28. PubMed ID: 26676775
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-Level Ionizing Radiation Induces Selective Killing of HIV-1-Infected Cells with Reversal of Cytokine Induction Using mTOR Inhibitors.
    Pinto DO; DeMarino C; Vo TT; Cowen M; Kim Y; Pleet ML; Barclay RA; Noren Hooten N; Evans MK; Heredia A; Batrakova EV; Iordanskiy S; Kashanchi F
    Viruses; 2020 Aug; 12(8):. PubMed ID: 32823598
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex Vivo.
    Timmons A; Fray E; Kumar M; Wu F; Dai W; Bullen CK; Kim P; Hetzel C; Yang C; Beg S; Lai J; Pomerantz JL; Yukl SA; Siliciano JD; Siliciano RF
    Proc Natl Acad Sci U S A; 2020 Jul; 117(27):15763-15771. PubMed ID: 32571938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal of Latency as Part of a Cure for HIV-1.
    Rasmussen TA; Tolstrup M; Søgaard OS
    Trends Microbiol; 2016 Feb; 24(2):90-97. PubMed ID: 26690612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined single-cell transcriptional, translational, and genomic profiling reveals HIV-1 reservoir diversity.
    Sannier G; Dubé M; Dufour C; Richard C; Brassard N; Delgado GG; Pagliuzza A; Baxter AE; Niessl J; Brunet-Ratnasingham E; Charlebois R; Routy B; Routy JP; Fromentin R; Chomont N; Kaufmann DE
    Cell Rep; 2021 Aug; 36(9):109643. PubMed ID: 34469719
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual effects of the novel ingenol derivatives on the acute and latent HIV-1 infections.
    Yang H; Li X; Yang X; Lu P; Wang Y; Jiang Z; Pan H; Zhao L; Zhu Y; Khan IU; Shen Y; Lu H; Zhang T; Jiang G; Ma Z; Wu H; Zhu H
    Antiviral Res; 2019 Sep; 169():104555. PubMed ID: 31295520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gnidimacrin, a Potent Anti-HIV Diterpene, Can Eliminate Latent HIV-1 Ex Vivo by Activation of Protein Kinase C β.
    Lai W; Huang L; Zhu L; Ferrari G; Chan C; Li W; Lee KH; Chen CH
    J Med Chem; 2015 Nov; 58(21):8638-46. PubMed ID: 26509731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.